Skip to content

Study · Case report or series · n = 1 · 2022

5 results

Effects of Semaglutide on Glycemic Control and Weight Loss in a Patient with Prader-Willi Syndrome: A Case Report.

Sani E, Prato GD, Zenti MG, Bordugo A, Trombetta M, Bonora E

Endocrine, metabolic & immune disorders drug targets1 Jan 2022Cited by 6 (Europe PMC)

PMID35538810 (opens in a new tab)DOI10.2174/1871530322666220509225637 (opens in a new tab)PepBankPUB-35538810
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a 33-year-old man with Prader-Willi syndrome and poorly controlled diabetes, semaglutide 1 mg per week was followed by a fall in glycated hemoglobin from 11.1% to 7.2% over 12 months.

    In plain wordsIn one man with Prader-Willi syndrome and diabetes, glycated hemoglobin fell from 11.1% to 7.2% after 12 months of semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseGlycated hemoglobin after 12 months
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 mg per week · 12 monthsAs given in this study (human).

    Measurements

    Glycated hemoglobin
    11.1%
    baseline
    Glycated hemoglobin
    7.2%
    12 months

    Source sentences

    Summary
    important reduction in glycated hemoglobin levels (11.1% to 7.2%)
    1 context sentence
    Summary · context
    We report for the first time the use of semaglutide 1 mg per week in a 33-yearold man with Prader-Will syndrome complicated by poorly controlled diabetes and severe obesity.
  2. 02HumanCase report or seriesEfficacy outcome

    In a 33-year-old man with Prader-Willi syndrome and severe obesity, body weight fell from 99.5 kg to 94.3 kg after 12 months of semaglutide 1 mg per week.

    In plain wordsIn one man with Prader-Willi syndrome and obesity, body weight fell from 99.5 kg to 94.3 kg after 12 months of semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight after 12 months
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1 mg per week · 12 monthsAs given in this study (human).

    Measurements

    Body weight
    99.5 kg
    baseline
    Body weight
    94.3 kg
    12 months

    Source sentences

    Summary
    body weight (99.5 kg to 94.3 kg)
    1 context sentence
    Summary · context
    We report for the first time the use of semaglutide 1 mg per week in a 33-yearold man with Prader-Will syndrome complicated by poorly controlled diabetes and severe obesity.
  3. 03HumanCase report or seriesEfficacy outcome

    In a 33-year-old man with Prader-Willi syndrome, fat mass decreased notably after 12 months of semaglutide 1 mg per week.

    In plain wordsIn one man with Prader-Willi syndrome, fat mass fell notably after 12 months of semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseFat mass after 12 months
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1 mg per week · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    a notable decrease in fat mass and insulin requirements.
    1 context sentence
    Summary · context
    We report for the first time the use of semaglutide 1 mg per week in a 33-yearold man with Prader-Will syndrome complicated by poorly controlled diabetes and severe obesity.
  4. 04HumanCase report or seriesEfficacy outcome

    In a 33-year-old man with Prader-Willi syndrome and poorly controlled diabetes, insulin requirements decreased notably after 12 months of semaglutide 1 mg per week.

    In plain wordsIn one man with Prader-Willi syndrome and diabetes, the insulin dose he needed fell notably after 12 months of semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseInsulin requirements after 12 months
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1 mg per week · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    a notable decrease in fat mass and insulin requirements.
    1 context sentence
    Summary · context
    We report for the first time the use of semaglutide 1 mg per week in a 33-yearold man with Prader-Will syndrome complicated by poorly controlled diabetes and severe obesity.
  5. 05HumanCase report or seriesEfficacy outcome

    In a man with Prader-Willi syndrome, earlier liraglutide added to metformin and insulin had no substantial efficacy.

    In plain wordsIn one man with Prader-Willi syndrome, earlier liraglutide treatment added to metformin and insulin had no substantial effect.

    Peptide
    Liraglutide
    Outcome
    No significant changeResponse to prior liraglutide added to metformin and insulin
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Interestingly, our patient had already tried liraglutide therapy in adjunction to metformin and insulin therapy, reporting no substantial efficacy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.